YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
97 hedge funds and large institutions have $716M invested in Y-mAbs Therapeutics in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 41 increasing their positions, 29 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
17% less capital invested
Capital invested by funds: $866M → $716M (-$150M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $665K
Holders
97
Holding in Top 10
2
Calls
–
Puts
$665K
Top Buyers
| 1 | +$10.6M | |
| 2 | +$4.81M | |
| 3 | +$3.58M | |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.46M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$3.3M |
Top Sellers
| 1 | -$10.6M | |
| 2 | -$8.56M | |
| 3 | -$6.69M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.87M |
| 5 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$3.75M |